{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"401"}],"units":"Participants"}],"title":"Post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"740"}],"units":"Participants"}],"description":"ADA-positive participants after drug administration were determined for participants exposed to trastuzumab emtansine. For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result. The total number of participants who developed ADAs to trastuzumab emtansine was determined by summing the ADA-positive participants across all timepoints.","groups":[{"description":"Participants received trastuzumab emtansine, 3.6 mg/kg, IV, Q3W for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG000","title":"Trastuzumab Emtansine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"SE Population included all randomized participants who received any amount of study treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline (Day1 of Cycle1) and Post Baseline (Day 1 of Cycle 4 up to 3-4 months after last dose of the drug [up to approximately 13.6 months])","title":"Number of Participants With Positive Anti-drug Antibodies (ADAs) to Trastuzumab Emtansine","type":"SECONDARY","unitOfMeasure":"Participants"}